• Dr. rer. nat. Andreas Hartlep
    Chief Executive Officer
  • Wolfgang Grillenberger
    Chief Commercial Officer
  • Dr. Robert Pfeffer
    Chief Financial Officer
  • Thomas Zschaeck
    Director Research & Development
  • Dr. med. Martin Hyca
    Director Marketing & Sales

t-VNS provides advantages for patients. There are no surgical risks and there are only minor side effects. As patients use NEMOS autonomously, the therapy can be easily integrated into the daily routine.

Dr. Andreas Hartlep (CEO)


Do you have questions regarding NEMOS® and t-VNS® therapy? Please get in touch with us.

Please note: NEMOS® is not cleared or approved for use in the U.S.